 |
|
JOURNAL CLUB
Metformin Extended Release Treatment of Adolescent ObesityA 48-Week Randomized, Double-Blind, Placebo-Controlled Trial With 48-Week Follow-up
Glaser Pediatric Research Network Obesity Study Group
Arch Pediatr Adolesc Med. 2010;164(2):116-123.
Background Metformin has been proffered as a therapy for adolescent obesity, although long-term controlled studies have not been reported.
Objective To test the hypothesis that 48 weeks of daily metformin hydrochloride extended release (XR) therapy will reduce body mass index (BMI) in obese adolescents, as compared with placebo.
Design Multicenter, randomized, double-blind, placebo-controlled clinical trial.
Setting The 6 centers of the Glaser Pediatric Research Network from October 2003 to August 2007.
Participants Obese (BMI 95th percentile) adolescents (aged 13-18 years) were randomly assigned to the intervention (n = 39) or placebo groups.
Intervention Following a 1-month run-in period, subjects following a lifestyle intervention program were randomized 1:1 to 48 weeks' treatment with metformin hydrochloride XR, 2000 mg once daily, or an identical placebo. Subjects were monitored for an additional 48 weeks.
Main Outcome Measure Change in BMI, adjusted for site, sex, race, ethnicity, and age and metformin vs placebo.
Results After 48 weeks, mean (SE) adjusted BMI increased 0.2 (0.5) in the placebo group and decreased 0.9 (0.5) in the metformin XR group (P = .03). This difference persisted for 12 to 24 weeks after cessation of treatment. No significant effects of metformin on body composition, abdominal fat, or insulin indices were observed.
Conclusion Metformin XR caused a small but statistically significant decrease in BMI when added to a lifestyle intervention program.
Trial Registration clinicaltrials.gov Identifiers: NCT00209482 and NCT00120146
Author Affiliations: Authors: Darrell M. Wilson, MD (chair); Stephanie H. Abrams, MD; Tandy Aye, MD; Phillip D. K. Lee, MD; Carine Lenders, MD, MS, ScD; Robert H. Lustig, MD; Stavroula V. Osganian, MD, ScD; Henry A. Feldman, PhD.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Analysis of Metformin Treatment for Adolescent Obesity at 48 Rather Than 24 Weeks After Treatment Cessation
Sana R. Sukkari, Larry D. Sasich, Abdullah S. Humaidan, and Omar Burikan
Arch Pediatr Adolesc Med. 2010;164(7):678.
EXTRACT
| FULL TEXT
Analysis of Metformin Treatment for Adolescent Obesity at 48 Rather Than 24 Weeks After Treatment Cessation—Reply
Darrell M. Wilson
Arch Pediatr Adolesc Med. 2010;164(7):678-679.
EXTRACT
| FULL TEXT
RELATED ARTICLE
This Month in Archives of Pediatrics & Adolescent Medicine
Arch Pediatr Adolesc Med. 2010;164(2):114.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The DASH Diet Predicts Weight Gain: What Does This Mean for My Pediatric Practice?
Klesges and Hare
Arch Pediatr Adolesc Med 2011;165:567-568.
FULL TEXT
Review: metformin is effective at attenuating the metabolic risks associated with use of atypical antipsychotics
Klein and Saldana
Evid. Based Ment. Health 2011;14:55-55.
FULL TEXT
Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children: A Randomized Clinical Trial
Yanovski et al.
Diabetes 2011;60:477-485.
ABSTRACT
| FULL TEXT
Pharmacologic Treatment for Adolescent Obesity
Smith
AAP Grand Rounds 2010;24:8-8.
FULL TEXT
Analysis of Metformin Treatment for Adolescent Obesity at 48 Rather Than 24 Weeks After Treatment Cessation
Sukkari et al.
Arch Pediatr Adolesc Med 2010;164:678-678.
FULL TEXT
Use of Metformin in Obese Adolescents
JWatch Pediatrics 2010;2010:2-2.
FULL TEXT
|
